The formation of desethyl-piperacillin from piperacillin by human liver S9 in vitro

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 3, 1997, Pages 185-190

  Komuro, Masahito ^a   Maeda, Toshimatsu ^a   Hayakawa, Hiroyoshi ^b   Allen, Katherine L ^c   Green, Carol E ^d  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b TOYAMA CHEMICAL CO LTD   (Japan)

^c BIOGEN   (United States)

^d SRI INTERNATIONAL   (United States)

Author keywords

human liver; in vitro metabolism; piperacillin; xenobiotic metabolism

Indexed keywords

DEETHYLPIPERACILLIN; DRUG METABOLITE; PIPERACILLIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG METABOLISM; DRUG TISSUE LEVEL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CORTEX; KIDNEY MEDULLA; LIVER METABOLISM;

EID: 0030937992     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199704)18:3<185::AID-BDD10>3.0.CO;2-U     Document Type: Article

References (11)

1. Y. Minami, M. Komuro, K. Sakawa, N. Ishida, K. Matsumoto et al., Desethyl piperacillin, a new active metabolite of piperacillin in human. J. Antibiot., 44, 256-258 (1991).
2. H. Matsushita, M. Komuro, T. Maeda, Y. Minami and K. Sakawa, Studies on metabolism of tazobactam/piperacillin in some animals. Chemotherapy, 42S-2, 198-205 (1994).
3. I. Saikawa, A. Takai, Y. Nakashima, C. Yoshida, T. Yasuda et al., Studies on β-lactam antibiotics for medicinal purpose. VI. Studies on the metabolism of 6-[D(-)-α-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-phenylacetamido] penicillanic acid (T-1220). Yakugaku Zasshi, 97, 1071-1081 (1977).
4. O. H. Lowry, J. J. Rosenbrough, A. L. Farr and R. S. Randall, Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275 (1951).
5. K. Matsumoto, T. Nagatake, T. Oishi, T. Amamoto, R. Urae et al., Tazobactam/piperacillin (TAZ/PIPC); phase I clinical trial. Chemotherapy, 42 S-2, 281-299 (1994).
6. M. Komuro, T. Maeda, H. Kakuo, H. Matsushita and J. Shimada, Inhibition of the renal excretion of tazobactam by piperacillin. J. Antimicrob. Chemother., 34, 555-564 (1994).
7. T. Terasaki, A. Tsuji, E. Nakashima, K. Nishide, C. H. Nightingale et al., Comparative pharmacokinetics of cefazolin in awake and urethane-anesthetized rats. Chem. Pharm. Bull., 33, 2153-2157 (1985).
8. A. Tsuji, T. Yoshioka, K. Nishide, H. Minami, M. Kimura et al., Physiological based pharmacokinetic model for β-lactam antibiotics I: tissue distribution and elimination in rats. J. Pharm. Sci., 72, 1239-1252 (1983).
9. H. Tanimura, K. Uchiyama, K. Ishimoto, S. Mukaihara, M. Noguchi et al., Tissue concentration and clinical effect of tazobactam/piperacillin in surgical infections. Chemotherapy, 42 S-2, 612-626 (1994).
10. I. Saikawa, T. Yasuda, H. Taki, Y. Watanabe, N. Matsubara et al., Absorption, excretion and tissue distribution of T-1220. Chemotherapy, 25, 801-809 (1977).
11. J. Van Cantfort, J. De Graeve and C. Puozzo, Difference in the metabolism of epicainide in rats and man. Xenobiotica, 19, 11-23 (1989).